Similarly, 60–65 % of GBS patients tested positive for both Campylobacter-specific IgA and IgG antibodies; it therefore follows that 34–49 % (≈42 %) of GBS cases in this study are statistically associated with campylobacteriosis. This evidence concerns the gene CD79A and Guillain-Barre syndrome.